270 related articles for article (PubMed ID: 15643424)
1. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.
Xu W; Yuan X; Xiang Z; Mimnaugh E; Marcu M; Neckers L
Nat Struct Mol Biol; 2005 Feb; 12(2):120-6. PubMed ID: 15643424
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARbeta activity.
Sumanasekera WK; Tien ES; Davis JW; Turpey R; Perdew GH; Vanden Heuvel JP
Biochemistry; 2003 Sep; 42(36):10726-35. PubMed ID: 12962497
[TBL] [Abstract][Full Text] [Related]
3. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
[TBL] [Abstract][Full Text] [Related]
5. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90.
Itoh H; Ogura M; Komatsuda A; Wakui H; Miura AB; Tashima Y
Biochem J; 1999 Nov; 343 Pt 3(Pt 3):697-703. PubMed ID: 10527951
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.
Xu W; Mimnaugh E; Rosser MF; Nicchitta C; Marcu M; Yarden Y; Neckers L
J Biol Chem; 2001 Feb; 276(5):3702-8. PubMed ID: 11071886
[TBL] [Abstract][Full Text] [Related]
7. The Ah receptor is a sensitive target of geldanamycin-induced protein turnover.
Chen HS; Singh SS; Perdew GH
Arch Biochem Biophys; 1997 Dec; 348(1):190-8. PubMed ID: 9390191
[TBL] [Abstract][Full Text] [Related]
8. Geldanamycin, a heat shock protein 90-binding agent, disrupts Stat5 activation in IL-2-stimulated cells.
Xu W; Yu F; Yan M; Lu L; Zou W; Sun L; Zheng Z; Liu X
J Cell Physiol; 2004 Feb; 198(2):188-96. PubMed ID: 14603521
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury.
Gabrielson K; Bedja D; Pin S; Tsao A; Gama L; Yuan B; Muratore N
Cancer Res; 2007 Feb; 67(4):1436-41. PubMed ID: 17308081
[TBL] [Abstract][Full Text] [Related]
11. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
Kamal A; Thao L; Sensintaffar J; Zhang L; Boehm MF; Fritz LC; Burrows FJ
Nature; 2003 Sep; 425(6956):407-10. PubMed ID: 14508491
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM
Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378
[TBL] [Abstract][Full Text] [Related]
13. Inside the Hsp90 inhibitors binding mode through induced fit docking.
Lauria A; Ippolito M; Almerico AM
J Mol Graph Model; 2009 Feb; 27(6):712-22. PubMed ID: 19084447
[TBL] [Abstract][Full Text] [Related]
14. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37.
Nony P; Gaude H; Rossel M; Fournier L; Rouault JP; Billaud M
Oncogene; 2003 Dec; 22(57):9165-75. PubMed ID: 14668798
[TBL] [Abstract][Full Text] [Related]
15. Geldanamycin prevents nuclear translocation of mutant p53.
Dasgupta G; Momand J
Exp Cell Res; 1997 Nov; 237(1):29-37. PubMed ID: 9417863
[TBL] [Abstract][Full Text] [Related]
16. Geldanamycin-induced PCNA degradation in isolated Hsp90 complex from cancer cells.
Wang X; Heuvelman DM; Carroll JA; Dufield DR; Masferrer JL
Cancer Invest; 2010 Jul; 28(6):635-41. PubMed ID: 20394503
[TBL] [Abstract][Full Text] [Related]
17. Cdk2: a genuine protein kinase client of Hsp90 and Cdc37.
Prince T; Sun L; Matts RL
Biochemistry; 2005 Nov; 44(46):15287-95. PubMed ID: 16285732
[TBL] [Abstract][Full Text] [Related]
18. The neuroblastoma tumour-suppressor TrkAI and its oncogenic alternative TrkAIII splice variant exhibit geldanamycin-sensitive interactions with Hsp90 in human neuroblastoma cells.
Farina AR; Tacconelli A; Cappabianca L; Cea G; Chioda A; Romanelli A; Pensato S; Pedone C; Gulino A; Mackay AR
Oncogene; 2009 Nov; 28(46):4075-94. PubMed ID: 19734938
[TBL] [Abstract][Full Text] [Related]
19. Molybdate inhibits hsp90, induces structural changes in its C-terminal domain, and alters its interactions with substrates.
Hartson SD; Thulasiraman V; Huang W; Whitesell L; Matts RL
Biochemistry; 1999 Mar; 38(12):3837-49. PubMed ID: 10090774
[TBL] [Abstract][Full Text] [Related]
20. MUC1 oncoprotein is targeted to mitochondria by heregulin-induced activation of c-Src and the molecular chaperone HSP90.
Ren J; Bharti A; Raina D; Chen W; Ahmad R; Kufe D
Oncogene; 2006 Jan; 25(1):20-31. PubMed ID: 16158055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
